Healthy lifestyle or Chronic Kidney Disease:The Choice is yours!

| June 3, 2019

article image
Chronic kidney disease (CKD) is a growing health problem with an estimated prevalence of around 11.5%.Individuals with CKD are at high risk for progressive kidney failure. End-stage kidney disease leads to considerable human and financial costs with a 5-year survival rate of less than 50%.  There are well-established risk factors for end-stage kidney disease of which Diabetes and hypertension are strong predictors for the development and progression of chronic kidney diseases and these in turn are closely linked to lifestyle factors. We have learned from research of other chronic conditions such as heart disease and cancer that lifestyle factors namely diet, physical activity, cigarette smoking, and body mass index plays a very important role in health outcomes namely cardiovascular events and mortality and kidney diseases are no exception to this rule. Over the next decade, the number of patients with end-stage renal disease requiring dialysis may double, and even developed nations will have difficulty coping with this alarming epidemic. There is an urgent need to highlight the importance of modifiable lifestyle risk factors as a basis for treatment strategies to prevent the development and progression of chronic kidney disease

Spotlight

NuPharm Laboratories Ltd

NuPharm Laboratories, a pharmaceutical development and manufacturing company, provides a wide range of services and products.

OTHER ARTICLES

5 Pharma Trends and Their Impact on Packaging

Article | February 27, 2020

The pharmaceutical industry is changing at an unprecedented pace. New biological treatments for cancer, and a dramatic rise of widespread diseases such as diabetes, call for new processing and packaging solutions to fulfill the different needs all over the world. Keep your eye on these five main packaging trends for 2020 for the global pharmaceutical market.

Read More

Clinical Development Risks and Issues in a COVID-19 World

Article | March 20, 2020

Global clinical guidelines have shifted the industry toward risk-based approaches for the planning and execution of clinical trials. The ICH’s guidelines for Good Clinical Practice state that sponsors should evaluate identified risks against existing risk controls by considering “the likelihood of errors occurring, the extent to which such errors would be detectable, and the impact of such errors on human subject protection and reliability of trial results” (ICH E6 R2).

Read More

Merck’s Patient-Centric Clinical Trial Recruiting

Article | March 4, 2020

Everyone in pharma knows that product success depends on the results of clinical trials — but we don’t usually hear from the people who are involved in running them. Recently, four Clinical Research Managers (CRM) from Merck (known as MSD outside the United States and Canada) discussed how Merck is overcoming the barriers to clinical trial recruitment by adopting a patient-centric process — a model that affects their trials top to bottom, from design through implementation. Each of the panel members manages clinical trials, serving as the main point of interaction with the Clinical Research Associates (CRAs) on research requirements, goals, and resources, including recruiting and retention.

Read More

As Pandemic Continues, Rafael Pharmaceuticals Enrolls Patients in Phase III Pancreatic Cancer Trial

Article | April 17, 2020

That simple truth about the severity of the disease is one of the reasons that Rafael Pharmaceuticals is slowly continuing with a Phase III trial in metastatic pancreatic cancer during the COVID-19 pandemic. While many companies have paused enrollment in clinical trials during the outbreak, Cranbury, N.J,-based Rafael opted to continue to enroll patients in its Phase III AVENGER 500 study of its lead compound CPI-613 (devimistat) in combination with modified Folfirinox (mFFX) as first-line therapy for the disease. Sanjeev Luther, president and chief executive officer of Rafael Pharmaceuticals, told BioSpace that the company made the decision to continue to enroll the trial, which was 75% filled, due to the short timeline patients with metastatic pancreatic cancer have. After discussing the matter of the trial with the company’s leadership team, Luther said they felt comfortable leaving the decision of whether or not the trial should continue to the conducting institute.

Read More

Spotlight

NuPharm Laboratories Ltd

NuPharm Laboratories, a pharmaceutical development and manufacturing company, provides a wide range of services and products.

Events